A.P. Pharma, Inc. (OTC:APPA) rolled up exploding in preceding months to the highs of $0.90 per share. The stock fell back to its support level where investors are guessing the stock to move up again.
The interesting part of APPA is that the company's lead product APF530 for the treatment of nausea and vomiting induced by chemotherapy treatment in patients. The product had remained under review for the approval by FDA. However the stock has seen sharp declines on as recently the FDA rejected its lead product.
According to a resource APF530 creates up to $900 million worth opportunity in the US only, where in 2011 5.1 million injectable vials were directed. Another eye catching feature for investors was chunks of stocks possessed by hedge funds and qualified investors like Baker Brothers, Tang Capital Management and Perceptive Advisors.
A.P. Pharma is a specialty pharmaceutical company engaging in development of products by using its proprietary Biochronomer™ polymer-based system drug delivery system. This drug delivery system intends to improvise the injectable products by converting them to the products that would be needed only once a week or two from the ones needed once or twice per day.
For more information and insights on A.P.Pharma, Inc. please click here: APPA
OTCMagic.com is quickly becoming the preeminent destination for up to date information on the hottest stocks in Penny stock World
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.